Boston Scientific Welcomes Revised Outlook From Fit...(e forward-looking statements are based o...)

Date:6/9/2008

e forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our financial performance, our programs to increase shareholder value, new product approvals, our expense reduction initiatives, our capital needs and expenditures, potential acquisitions and divestitures, our debt repayment strategy, our operational strategy, our growth strategy, market recovery and our market position. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and, future business decisions made by us and our competitors. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A - Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A - Risk Factors in Quarterly Reports on Form 1
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Boston Scientific to Participate in Goldman Sachs Conference
2. Boston Scientific Announces CEO Jim Tobin to Extend Tenure
3. NanoLogix Inc. to Present at The American Society for Microbiology (ASM) General Meeting in Boston; Announces Product Line and Provides Operations Update
4. Boston Scientific Completes Acquisition of CryoCor
5. Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System
6. Boston Scientific Announces FDA Approval of New Heart Failure Lead
7. Boston Scientifics SpyGlass(R) Direct Visualization System to Be Prominently Featured at Digestive Disease Week(R)
8. Boston Scientific Announces Program to Analyze Latitude(R) Patient Monitoring Data
9. Boston Scientific Announces European Approval and Market Launch of New Family of Advanced Pacemakers
10. WIPO Panel Rules Boston Scientific Liberte(R) and TAXUS(R) Liberte(R) Stents Do Not Infringe Medinol Patents
11. Fraunhofer and Boston University Hosted Prestigious SME Tour